Pfizer to help Western Oncolytics move gene therapy through Phase I trials

Story excerpt provided by Crain’s Cleveland Business.

Written by Chuck Soder.

Pfizer plans to help Western Oncolytics move its gene therapy through Phase I clinical trials — and it could buy the company if those trials go well.

Under the agreement, Pfizer will work with the small Westlake-based company to complete animal trials and Phase I clinical trials. Afterward it would have the exclusive option to acquire the drug, according to a news release from the two companies.

The drug, which is called WO-12, is designed to fight cancer in multiple ways.

Click here to read the complete article.

Originally published July 28, 2016.